兒童低惡性度神經膠質瘤市場:KOL的洞察

本報告提供全球兒童低惡性度神經膠質瘤市場相關調查，市場概要，以及已通過核准治療方法，開發平台趨勢，未來預測等資訊。

目錄

摘要整理

兒童低惡性度神經膠質瘤的現在及未來的治療流程

調查目的

後期開發平台

• II型泛Raf激化酵素抑制劑
  • Tovorafenib
• MEK抑制劑
  • Selumetinib
• MEK抑制劑+I型BRAF抑制劑
  • Trametinib+ Dabrafenib
• 其他的作用機制
  • Everolimus
  • Bevacizumab

兒童低惡性度神經膠質瘤的治療的未來趨勢與機會

附錄

KOL快報

Targeted therapies to become standard of care in paediatric low-grade glioma. How do KOLs assess the potential of targeted drugs as front-line therapies? Day One's tovorafenib set for front line position in paediatric low-grade glioma. What clinical advantages do KOLs identify for this late-stage pan-RAF inhibitor? Leading KOLs critically assess the prospects of pipeline therapies for treating paediatric low-grade glioma.

Table of Contents

Executive summary (13)

Current and future treatment algorithm for pLGG

Research objectives (2)

Late-stage pipeline drugs (81)

• Type II pan-Raf kinase inhibitor (26)
  • Tovorafenib (Day One Biopharmaceuticals) (26)
• MEK inhibitor (21)
  • Selumetinib (Koselugo; AstraZeneca/Merck & Co) (21)
• MEK inhibitor + type I BRAF inhibitor (16)
  • Trametinib + dabrafenib (Mekinist + Tafinlar; Novartis) (16)
• Other mechanisms of action (18)
  • Everolimus (Afinitor; Novartis) (6)
  • Bevacizumab (Avastin; Roche) (12)

Future trends and opportunities in pLGG treatment (11)

Appendix (5)

• KOL details (5)
  • KOLs from North America (3)
  • KOLs from Europe (1)

KOL Bulletins (2)